Art. -Nr.: HY-148748

Butyzamide

4 Cited Publications

Kundenbewertung

Based on 4 publication(s) in Google Scholar

Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.83%
CAS. Nr.: 1110767-45-7
Formel: C₂₉H₃₂Cl₂N₂O₅S
Molecular Weight:591.55

Speicherung:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Butyzamide Chemical Structure

CAS. Nr.: 1110767-45-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

JAK2

STAT3

STAT5

Alle JAK Isoform-spezifische Produkte anzeigen :

Alle STAT Isoform-spezifische Produkte anzeigen :

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

In Vitro

Butyzamide (3 μM; 15 min) induces the phosphorylation of JAK2, STAT3, STAT5 and MAPK in Ba/F3-hMpl cells^[1].
Butyzamide (3 μM; 48 h) induces colony-forming unit-megakaryocyte and polyploid meggakaryocytes from human CD34⁺ hematopoietic progenitor cellls^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Butyzamide (10 mg/kg, 50 mg/kg; p.o.; once daily for 20 days) increases human platelets in NOG mice transplanted with human fetal liver-derived CD34⁺ cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1110767-45-7
Appearance Solid
Molecular Weight 591.55
Formel C₂₉H₃₂Cl₂N₂O₅S
Color White to off-white
SMILES

CCCOC(C(C)(C)C)C1=CC=CC(C2=CSC(NC(C3=CC(Cl)=C(/C=C(C(O)=O)\C)C(Cl)=C3)=O)=N2)=C1OC
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (4)

All IFWBCell Imaging/StainingFlow Cytometry

Sort by:

Journal Impact Factor

Phytomedicine

Cryptotanshinone attenuates lactate-induced nucleus pulposus cells injury by modulating the STAT3/SIRT3 signaling axis. [Abstract]

2025 Sep:145:157021. PMID: 40609385

Butyzamide purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Sep:145:157021. [Abstract]

Results of SIRT3 immunofluorescence staining in Cry-treated NPCs after addition of the STAT3 activator Butyzamide (Bym) (3 μM). Butyzamide (Bym) markedly reduced the therapeutic effect of Cry in NPCs.

Butyzamide purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Sep:145:157021. [Abstract]

The addition of the STAT3 activator Butyzamide (Bym) (3 μM) attenuated the activation of SIRT3 by Cry under lactate induction in NPCs.

Butyzamide purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Sep:145:157021. [Abstract]

The addition of Butyzamide (Bym) (3 μM) led to a significant reduction in the antioxidant effect of Cry in NPCs.

Butyzamide purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Sep:145:157021. [Abstract]

Butyzamide (Bym) (3 μM) reversed the therapeutic benefits of Cry against apoptosis in NPCs, as indicated by flow cytometry assays.
Int J Nanomedicine

RGD-Modified Gold Nanoparticles Loaded with SAHA Remodel the Hypoxic Inflammatory Microenvironment via Inhibiting HIF-1α-VEGF Signaling to Enhance Radiosensitivity in NSCLC. [Abstract]

2025 Dec 10:20:14753-14785. PMID: 41409042

Butyzamide purchased from MedChemExpress. Usage Cited in: Int J Nanomedicine. 2025 Dec 10:20:14753-14785. [Abstract]

Butyzamide (3 μM) reversed the inhibition of RGD-AuNPs-SAHA towards the JAK2/STAT3 signaling pathway and increased the phosphorylation levels of JAK2 and STAT3 in A549 cells.
bioRxiv

Epigenome editing of human hematopoietic stem cells enables sustained and reversible thrombosis prevention. [Abstract]

2026 Mar 29:2026.03.27.714536. PMID: 41928991
bioRxiv

Inherited resilience to clonal hematopoiesis by modifying stem cell RNA regulation. [Abstract]

2025 Mar 26:2025.03.24.645017. PMID: 40196615

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (169.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6905 mL

8.4524 mL

16.9047 mL

5 mM

0.3381 mL

1.6905 mL

3.3809 mL

10 mM

0.1690 mL

0.8452 mL

1.6905 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Nogami W, et al. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis. Haematologica. 2008 Oct;93(10):1495-504. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6905 mL	8.4524 mL	16.9047 mL	42.2619 mL
	5 mM	0.3381 mL	1.6905 mL	3.3809 mL	8.4524 mL
	10 mM	0.1690 mL	0.8452 mL	1.6905 mL	4.2262 mL
	15 mM	0.1127 mL	0.5635 mL	1.1270 mL	2.8175 mL
	20 mM	0.0845 mL	0.4226 mL	0.8452 mL	2.1131 mL
	25 mM	0.0676 mL	0.3381 mL	0.6762 mL	1.6905 mL
	30 mM	0.0563 mL	0.2817 mL	0.5635 mL	1.4087 mL
	40 mM	0.0423 mL	0.2113 mL	0.4226 mL	1.0565 mL
	50 mM	0.0338 mL	0.1690 mL	0.3381 mL	0.8452 mL
	60 mM	0.0282 mL	0.1409 mL	0.2817 mL	0.7044 mL
	80 mM	0.0211 mL	0.1057 mL	0.2113 mL	0.5283 mL
	100 mM	0.0169 mL	0.0845 mL	0.1690 mL	0.4226 mL

Keywords

Butyzamide

4 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Butyzamide

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

MAPK Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Osteogenesis Compound Library

Coagulation and Anti-coagulation Compound Library

Pain-Related Compound Library

Autoimmune Disease Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Butyzamide

Alle JAK Isoform-spezifische Produkte anzeigen

Alle STAT Isoform-spezifische Produkte anzeigen

Alle p38 MAPK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (4)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Butyzamide Related Classifications

HY-148748 Related Classifications